ArticleiScience2023

Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by Omicron.

Jakob Kreye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.